
|Articles|March 1, 2020
- Pharmaceutical Executive-03-01-2020
- Volume 40
- Issue 3
Pharmaceutical Executive, March 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
The Multichannel Reach: Balancing the Local and Global Voicealmost 6 years ago
Market Access: From Being to Becomingalmost 6 years ago
Consider Data Before It’s a Problemalmost 6 years ago
Multichannel Marketing: Integrating Omnichannelalmost 6 years ago
Feds Target Biosimilar Anticompetitive Practicesalmost 6 years ago
Blood Feud Divides Europe Over Plasma Shortfallsalmost 6 years ago
Social Media’s Influence in Messaging Mixalmost 6 years ago
Habib Bennaceur: Following the Sciencealmost 6 years ago
A Bad Deal with Data?almost 6 years ago
Country Report: United Arab EmiratesNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Your Phase III Clinical Protocol Is Your Initial Product Launch
2
Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements
3
AstraZeneca Enters $4.7 Billion Collaboration Agreement with CSPC Pharmaceuticals
4
Taking Advantage of ‘Hidden Gem’ Talent Hubs
5




